Mutations are the changes in the DNA that gradually occur in human cells as they replicate, and the organism grows and ages.
Some of these changes, particularly when they occur in genes, can be instrumental during the development of cancer.
Therefore, it is important to differentiate changes that have the potential of being relevant for the disease against others that will accumulate without consequence.
The understanding and characterisation of the harmless changes is a key methodology used to detect other changes that differ from them and can lead to a better identification of those that are harmful.
In a study published in Nucleic Acids Research, ICREA researcher Dr. Fran Supek and Dr. David Mas Ponte, both at IRB Barcelona, have uncovered variations of mutation rates at a fine scale within genes.
Through this study, they have identified “coldspots”, where the mutation burden is lower than usual, and have linked them with low DNA methylation, a common epigenetic mark, thereby establishing a direct mechanism linked to their regulation.
"Understanding the distribution of mutation rates could facilitate the development of targeted therapies to protect specific genomic regions, or diagnostic tools to monitor these regions. Such therapies could help prevent the accumulation of mutations that drive cancer development or progression," says Dr. Supek.
These discoveries stemmed from performing data analysis on mutations found in cancer cells and healthy tissues, together with DNA methylation and other epigenetic datasets.
Mutations and epigenetics
Epigenetics encompasses chemical modifications on both DNA and the proteins that coat them, such as histones, and regulates gene expression without changing the DNA sequence.
DNA methylation is a natural process that can influence how active a gene is, it’s one of the most common epigenetic alterations and is particularly important for active genes as they are normally expressed in the tumour.
Contrary to other histone modifications, which occur across large sections of the gene, patterns of DNA methylation vary across short segments of the gene and thus are additionally relevant when quantifying the mutation rate variability across the genome and adjacent regulatory regions.
"This study enhances our understanding of factors contributing to uneven mutation distribution within genes, offering valuable insights into mutagenesis mechanisms and cancer evolution," Dr. Supek concludes.
This research project received funding from the European Research Council Consolidator Grant STRUCTOMATIC and the Spanish Ministry of Science and Innovation through a “Plan Nacional” grant and the Severo Ochoa Excellence Programme.
Source: Institute for Research in Biomedicine (IRB Barcelona)
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.